

In the Claims:

Please add new claims 74-81 as follows:

74. (New) The stable pharmaceutical formulation of claim 65, wherein the stable pharmaceutical formulation is prepared by wet granulation techniques, dry granulation techniques, or dry blending techniques.

75. (New) The formulation of claim 66, wherein the formulation is prepared by wet granulation techniques, dry granulation techniques, or dry blending techniques.

76. (New) The stable pharmaceutical formulation of claim 68, wherein the stable pharmaceutical formulation is prepared by wet granulation techniques, dry granulation techniques, or dry blending techniques.

77. (New) The pharmaceutical unit dosage form of an amino acid of claim 69, wherein the pharmaceutical unit dosage form of an amino acid is prepared by wet granulation techniques, dry granulation techniques, or dry blending techniques.

78. (New) The stable pharmaceutical formulation of claim 65, wherein the one or more amino acids are selected from the group consisting of ethyl 1-aminomethyl-1-cyclohexane acetate, 1-aminomethyl-1-cycloheptaneacetic acid, 1-aminomethyl-1-cyclopentaneacetic acid, methyl 1-aminomethyl-1-cyclohexane acetate, n-butyl 1-aminomethyl-1-cyclohexane acetate, methyl 1-aminomethyl-1-cycloheptane acetate, n-butyl 1-aminomethyl-1-cycloheptane acetate, toluene sulfonate, 1-aminomethyl-1-cyclopentane acetate, benzene sulfonate, and n-butyl 1-aminomethyl-1-cyclopentane acetate.

79. (New) The formulation of claim 66, wherein the at least one amino acid is selected from the group consisting of ethyl 1-aminomethyl-1-cyclohexane acetate, 1-aminomethyl-1-cycloheptaneacetic acid, 1-aminomethyl-1-cyclopentaneacetic acid, methyl 1-

aminomethyl-1-cyclohexane acetate, n-butyl 1-aminomethyl-1-cyclohexane acetate, methyl 1-aminomethyl-1-cycloheptane acetate, n-butyl 1-aminomethyl-1-cycloheptane acetate, toluene sulfonate, 1-aminomethyl-1-cyclopentane acetate, benzene sulfonate, and n-butyl 1-aminomethyl-1-cyclopentane acetate.

80. (New) The stable pharmaceutical formulation of claim 68, wherein the one or more active agents are selected from the group consisting of ethyl 1-aminomethyl-1-cyclohexane acetate, 1-aminomethyl-1-cycloheptaneacetic acid, 1-aminomethyl-1-cyclopentaneacetic acid, methyl 1-aminomethyl-1-cyclohexane acetate, n-butyl 1-aminomethyl-1-cyclohexane acetate, methyl 1-aminomethyl-1-cycloheptane acetate, n-butyl 1-aminomethyl-1-cycloheptane acetate, toluene sulfonate, 1-aminomethyl-1-cyclopentane acetate, benzene sulfonate, and n-butyl 1-aminomethyl-1-cyclopentane acetate.

81. (New) The pharmaceutical unit dosage form of an amino acid of claim 69, wherein the amino acid is selected from the group consisting of ethyl 1-aminomethyl-1-cyclohexane acetate, 1-aminomethyl-1-cycloheptaneacetic acid, 1-aminomethyl-1-cyclopentaneacetic acid, methyl 1-aminomethyl-1-cyclohexane acetate, n-butyl 1-aminomethyl-1-cyclohexane acetate, methyl 1-aminomethyl-1-cycloheptane acetate, n-butyl 1-aminomethyl-1-cycloheptane acetate, toluene sulfonate, 1-aminomethyl-1-cyclopentane acetate, benzene sulfonate, and n-butyl 1-aminomethyl-1-cyclopentane acetate.

REMARKS

Reconsideration and allowance of the above-captioned patent application is respectfully requested. Claims 1-4, 6-24, 26-44, 53-58, 60-66, and 68-73 were initially pending. Upon entry of the above described amendments, new claims 74-81 will be added. No new matter has been entered.